0.07
-7.14%
Close of 9 Nov 2026, in CAD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About VentriPoint Diagnostics
Its shares trade on TSX Venture under the ticker VPT.V. It has been listed since 9 November 2005. In the fiscal year to 31 December 2025, it reported revenue of C$179,928 and a net loss of C$3.2m. At that date it held total assets of C$472,082 and shareholders' equity of −C$4.1m.
VentriPoint Diagnostics Ltd. is a medical device company, which engages in the development and commercialization of diagnostic tools that monitor patients with heart disease. The company is headquartered in Toronto, Ontario. The company went IPO on 2005-11-09. The firm is engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. The company is developing a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, imaging, and cardiotoxicity in oncology patients. The Company’s Ventripoint Medical System (VMS+) is a diagnostic aid that was developed to provide a point-of-care solution to better communicate the heart’s structure and function without the need for magnetic resonance imaging (MRI). VMS+ enhances ultrasound, providing three-dimensional (3D) technology that allows for visualization of all four chambers of the heart. The system’s proprietary Knowledge Based Reconstruction (KBR) technology creates 3D models of the heart and calculates volumes and ejection fractions equivalent to the gold-standard Magnetic resonance imaging (MRI).
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 9 Nov 2005
- Website
- ventripoint.com ↗
Leadership
Pay as last reported
- Dr. George AdamsExecutive Chairman of the Board, since 2010C$346,828
- Dr. Alvira MacanovicPresident, Chief Executive OfficerC$217,575
- Mr. Jimmy JeonChief Financial Officer
- Mr. Randy AuCoinIndependent DirectorC$99,199
- Ms. Fiona FitzgeraldIndependent DirectorC$113,181
- Mr. Robert HodgkinsonIndependent DirectorC$18,135
- Mr. Hugh MacNaughtIndependent DirectorC$37,633
- Mr. Jonathan RobinsonIR Contact Officer, since 2022
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- VMS+ provides point-of-care diagnostic solutions without requiring magnetic resonance imaging equipment.
- Proprietary KBR technology creates 3D heart models equivalent to gold-standard MRI results.
- Applications cover diverse conditions including congenital heart disease and pulmonary hypertension.
Weaknesses
- The company relies on a single medical device system for its core business.
- VentriPoint Diagnostics Ltd operates in a niche market with limited product diversity.
- Commercialization efforts are focused primarily on heart disease monitoring tools.
Opportunities
- Expanding applications to include cardiotoxicity monitoring in oncology patients offers new revenue streams.
- Integrating the system with ultrasound devices enhances visualization of all four heart chambers.
- Addressing pregnancy-related heart conditions presents an additional segment for diagnostic tool adoption.
Threats
- Competition from established MRI technology providers may limit market adoption of VMS+.
- Regulatory hurdles for new diagnostic aids could delay commercialization of upcoming applications.
- Rapid technological advancements in ultrasound imaging might render current proprietary features obsolete.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.